Improving the Cardiorenal Usability of Endothelin Receptor Antagonism in Albuminuric Chronic Kidney Disease: A Testable Role for SGLT2 Inhibitor-based Mitigation of Fluid Retention.

Corrêa LMA, Brandão LKV, Delmiro Silva YR, Ferreira GD, Yoshimoto NH

Open source

DOI
10.1007/s10557-026-07909-z
Published
2026 Jul 8
Container
Cardiovascular drugs and therapy
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1007/s10557-026-07909-z,
  title = {Improving the Cardiorenal Usability of Endothelin Receptor Antagonism in Albuminuric Chronic Kidney Disease: A Testable Role for SGLT2 Inhibitor-based Mitigation of Fluid Retention.},
  author = {Corrêa LMA and Brandão LKV and Delmiro Silva YR and Ferreira GD and Yoshimoto NH},
  year = {2026},
  journal = {Cardiovascular drugs and therapy},
  doi = {10.1007/s10557-026-07909-z},
  url = {https://doi.org/10.1007/s10557-026-07909-z}
}

RIS

TY  - JOUR
TI  - Improving the Cardiorenal Usability of Endothelin Receptor Antagonism in Albuminuric Chronic Kidney Disease: A Testable Role for SGLT2 Inhibitor-based Mitigation of Fluid Retention.
AU  - Corrêa LMA
AU  - Brandão LKV
AU  - Delmiro Silva YR
AU  - Ferreira GD
AU  - Yoshimoto NH
PY  - 2026
JO  - Cardiovascular drugs and therapy
DO  - 10.1007/s10557-026-07909-z
UR  - https://doi.org/10.1007/s10557-026-07909-z
ER  - 

APA

LMA, C., LKV, B., YR, D. S., GD, F., & NH, Y. (2026). Improving the Cardiorenal Usability of Endothelin Receptor Antagonism in Albuminuric Chronic Kidney Disease: A Testable Role for SGLT2 Inhibitor-based Mitigation of Fluid Retention.. Cardiovascular drugs and therapy. https://doi.org/10.1007/s10557-026-07909-z

Source records